Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization
- PMID: 1898972
- PMCID: PMC239825
- DOI: 10.1128/JVI.65.2.852-860.1991
Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization
Abstract
Several parameters which may affect the infectivity of human immunodeficiency virus type 1 in tissue culture were analyzed. In particular, we used gel exclusion chromatography to investigate how the loss of the surface glycoprotein gp120 from virions of the HTLV-IIIB (IIIB), HTLV-IIIRF (RF), and SF-2 isolates modulates infectivity. In IIIB and RF cultures, a high proportion of the total gp120 was virion bound initially but was gradually lost from the virions over time. In contrast, most of the gp120 (and p24) in SF-2-infected cultures was soluble and the few particles present had a fivefold-lower level of virus-bound gp120. However, this reduced level of virion-bound gp120 was more resistant to shedding. Loss of a major proportion of gp120 from IIIB and RF virions resulted in reduced infectivities, and in addition, the resulting accumulation of soluble gp120 in the cultures could competitively inhibit viral infection, especially with SF-2. Increased shedding of virion gp120 also affected the neutralization of IIIB and RF particles. However, the high sensitivity to human serum neutralization characteristic of SF-2 was unaffected by soluble gp120 in cultures, suggesting that the epitopes responsible are not present on soluble gp120.
Similar articles
-
Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates.J Virol. 1992 Jan;66(1):235-43. doi: 10.1128/JVI.66.1.235-243.1992. J Virol. 1992. PMID: 1727487 Free PMC article.
-
Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus.Virology. 1992 Aug;189(2):695-714. doi: 10.1016/0042-6822(92)90593-e. Virology. 1992. PMID: 1386485
-
Direct measurement of soluble CD4 binding to human immunodeficiency virus type 1 virions: gp120 dissociation and its implications for virus-cell binding and fusion reactions and their neutralization by soluble CD4.J Virol. 1991 Mar;65(3):1133-40. doi: 10.1128/JVI.65.3.1133-1140.1991. J Virol. 1991. PMID: 1995942 Free PMC article.
-
Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120.J Virol. 1992 Feb;66(2):848-56. doi: 10.1128/JVI.66.2.848-856.1992. J Virol. 1992. PMID: 1370558 Free PMC article.
-
Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans.J Virol. 1993 Feb;67(2):863-75. doi: 10.1128/JVI.67.2.863-875.1993. J Virol. 1993. PMID: 7678308 Free PMC article.
Cited by
-
Mapping genetic determinants for human immunodeficiency virus type 1 resistance to soluble CD4.J Virol. 1992 May;66(5):3125-30. doi: 10.1128/JVI.66.5.3125-3130.1992. J Virol. 1992. PMID: 1373203 Free PMC article.
-
V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.J Clin Invest. 1993 Aug;92(2):840-7. doi: 10.1172/JCI116658. J Clin Invest. 1993. PMID: 8349820 Free PMC article. Clinical Trial.
-
Infectious properties of human immunodeficiency virus type 1 mutants with distinct affinities for the CD4 receptor.J Virol. 1997 Feb;71(2):883-90. doi: 10.1128/JVI.71.2.883-890.1997. J Virol. 1997. PMID: 8995604 Free PMC article.
-
Nascent human immunodeficiency virus type 1 reverse transcription occurs within an enveloped particle.J Virol. 1995 Jun;69(6):3675-82. doi: 10.1128/JVI.69.6.3675-3682.1995. J Virol. 1995. PMID: 7745716 Free PMC article.
-
A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells.J Virol. 1992 Aug;66(8):4784-93. doi: 10.1128/JVI.66.8.4784-4793.1992. J Virol. 1992. PMID: 1378510 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources